U.S. markets open in 9 hours 15 minutes

Myovant Sciences Ltd. (MYOV)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
23.53+1.68 (+7.69%)
At close: 1:00PM EST
Sign in to post a message.
  • V
    Vishwanath
    UROV another vant group was acquired today at 16.25 ( almost 100% premium ). MYOV is another Vant group with 51% owned by Sumitomo also, may be this will also be their next target to complete a similar acquisition of remaining 49% to get full control. Hope the price will be around 40 to 45$ if that happens in the near term.
    Bullish
  • j
    josh
    (MYOV) on Thursday reported a loss of $67.1 million in its fiscal second quarter.

    On a per-share basis, the London-based company said it had a loss of 75 cents.

    The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 78 cents per share.

    Myovant Sciences shares have climbed almost 7% since the beginning of the year. The stock has nearly tripled in the last 12 months.
  • S
    Steven
    Going to fly.
    Run up on approval
    Should set new highs this week
    Superior drug
  • Y
    Yahoo Finance Insights
    Myovant Sciences reached a 52 Week high at 23.32
  • V
    Vishwanath
    Almost at the finish line for formal approval. Expect 30-35$ once approved or may be a buy out / control by sumitomo during First qrtr of 2021 for a price in the range of 40-45$ hopefully. They already owe >51% of shares and like Urovant they will / may pull this one too. Any case a 30+ after Dec approval is likely for this oral medication.
    Bullish
  • V
    Vishwanath
    Yes they are dumping more than 51% they own and control by end of week LOL
    Then rebuy after next months approval at a higher price
    Bullish
  • J
    JBSINC
    MYOV shall be in no concern, TWO FDA set on Dec. 20, 2020 and June 1, 2021. MYOV has been under priced since the last mark. But we shall be looking good in Nov. and Dec. as there will be more triggering investments to MYOV
    Bullish
  • H
    Hotpicks
    (KTRA) MCap $35 M --Cash $24 M --2x BIG PHASE 3 Cancer Programs / important Phase 2 DATA IMMINENT / UNDISCOVERED stock = 1000%+ Upside Potential guys
    https://assets.wallstreet-online.de/_media/8763/board/20201112172159-screenshot-2020-11-12-powerpoint-presentation-kin.png

    +#+#+#+#
  • F
    FV
    Good news coming? People loading up?
  • J
    John
    Is stock price Ok here? What’s going on with the Myovante approvals? Am also looking at stock prices in $BCRX .
  • M
    MICHAEL
    Most annoying stock I’ve ever owned. Still up from purchase this spring but selling by 2021 if it doesn’t move
  • J
    Joe
    UP UP & away $45
  • M
    MICHAEL
    Thought myov was on recent trend to $20. Completely wrong, heading wrong way
  • M
    Mo$
    Myov is going up to $18-$20, filling the gap of when it gapped down. There are too many other drugs in its pipeline, it is drastically undervalued.
  • C
    Case
    Somutomo will soon sell his shares. All hype.
  • B
    Brendan
    Besides Relugolix (120 mg) which is under Priority Review by the FDA for the treatment of men with advanced prostate cancer, with a target action date of December 20, 2020, don't forget FDA Acceptance of New Drug Application for Once-Daily Relugolix Combination Tablet for Uterine Fibroids PDUFA date June 1, 2021. Additionally, Myovant submitted a Marketing Authorization Application to the European Medicines Agency in March 2020 for relugolix combination tablet for the treatment of women with uterine fibroids. Myovant has also reported positive data from two replicate Phase 3 studies evaluating relugolix combination therapy in women with endometriosis.
  • j
    josh
    “These new data from the Phase 3 HERO study show that three out of four men with metastatic prostate cancer remained castration resistance-free through 48 weeks while on oral relugolix, in-line with leuprolide acetate injections, the current standard of care,” said Dan George, M.D., a professor of medicine and surgery at the Duke University School of Medicine and HERO program steering committee member. “I continue to be excited by relugolix as a potential new and differentiated treatment option for men with prostate cancer given its robust clinical and safety data, including the lower risk of major adverse cardiovascular events compared to leuprolide acetate.”
  • u
    ut2003
    Any news causing the big drop today?
  • V
    Vishwanath
    Holding 15+ today. Once FDA approved in DEC, can we expect Sumitomo to buy the rest (49%) or so around $30 to 40$ range?
    Bullish
  • C
    Case
    Myov is going down because someone else built a better mousetrap.